Dr. Suzanne R. Fanning
Claim this profilePrisma Health Cancer Institute - Eastside
Studies Adult T-Cell Leukemia/Lymphoma
Studies Lymphoma
12 reported clinical trials
35 drugs studied
Area of expertise
1Adult T-Cell Leukemia/Lymphoma
BCR-ABL1 positive
FLT3 positive
13q positive
2Lymphoma
Stage I
13q positive
13q negative
Affiliated Hospitals
Clinical Trials Suzanne R. Fanning is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Iberdomide
for Multiple Myeloma
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Recruiting1 award Phase 210 criteria
More about Suzanne R. Fanning
Clinical Trial Related2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Suzanne R. Fanning has experience with
- Venetoclax
- Cytarabine
- Azacitidine
- Daunorubicin Hydrochloride
- Dexamethasone
- Cyclophosphamide
Breakdown of trials Suzanne R. Fanning has run
Adult T-Cell Leukemia/Lymphoma
Lymphoma
Acute Myeloid Leukemia
Lymphoid Hematopoietic Disease
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Suzanne R. Fanning specialize in?
Is Suzanne R. Fanning currently recruiting for clinical trials?
Are there any treatments that Suzanne R. Fanning has studied deeply?
What is the best way to schedule an appointment with Suzanne R. Fanning?
What is the office address of Suzanne R. Fanning?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.